Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Byoung Chul Cho, Delvys Rodríguez‐Abreu, Maen Hussein, Manuel Cobo, A. Patel, Nevena Sečen, Ki Hyeong Lee, Bartomeu Massutí, Sandrine Hiret, James Chih Hsin Yang, Fabrice Barlési, Dae Ho Lee, Luis Paz Ares, Robert W. Hsieh, Namrata S. Patil, Patrick J. Twomey, Xiaoying Yang, Raymond D. Meng, Melissa L. Johnson